OR WAIT null SECS
Though the pharma industry has improved its change management processes, there are still opportunities for improvement.
In the pharmaceutical industry, a change and deviation management system (CMS) is a central part of the overall quality management system for drug product manufacture — often referred to as the pharmaceutical quality system. In accordance with the ICH Q10 guideline, also supported by the FDA, CMS is one of the four key elements that make up a pharmaceutical quality system (the remaining three elements include process performance and product quality monitoring system; corrective action and preventive action (CAPA) system; management review of process performance and product quality).
(PATRICK KALYANAPU/GETTY IMAGES)
According to the FDA and International Conference on Harmonisation (ICH), a formal CMS should be established to evaluate all changes that could affect the production and control of the drug product, intermediate or API in a pharmaceutical manufacturing company. In addition, some level of CMS is also expected by the FDA for the production of clinical supplies; any changes in the production process and product formulation after the production of the phase III clinical batch must be tightly controlled and carefully evaluated from a product equivalency perspective. Significant process, formulation or equipment changes after the production and use of the phase III clinical batch could result in the performance of lengthy and costly bioequivalency and safety studies, and cause a delay in FDA product approval.
Although the cGMP regulation for drug products (21 CFR 211) has no direct reference to change control, change control is implied in 211.100(a) and 211.160(a). 211.100(a) requires that changes in production procedures and process controls be reviewed and approved by the appropriate organisation units and the quality control unit. This was a major component of Warning Letters issued by the FDA between 2007 and 2009. 211.160(a) requires a similar review and approval for changes related to laboratory controls, sampling plans, specifications, and analytical test methods.
The FDA considers change control a very critical GMP compliance issue; therefore it has been one of the main criteria used by the agency in determining their drug inspection depth and coverage, and their decision for follow-up regulatory actions (e.g., Warning Letter issuance). The FDA's strategy for drug inspection and follow-up is evidenced in their systems inspection programme introduced in 2002 for drug product inspection, and in 2006 for API inspection. The FDA compliance programme for drug product inspection (CP7356.002) instructs the FDA investigator to select the comprehensive inspection option when changes have been made that could impact cross-contamination control, or when there had been changes in technology, new facilities or equipment. The FDA compliance programme for API inspection (CP7356.002F) has the same requirements for the performance of a comprehensive inspection, along with additional criteria for changes related to starting materials, intermediates, equipment, facilities, support systems, processing steps, packaging materials or computer software. Both compliance programmes instruct the FDA district office to recommend regulatory actions when there is a pattern of the failure to establish or to follow a CMS.
Typical major GMP deficiencies related to CMS include:
When researching the subjects and the number of FDA Warning Letters issued, the pharmaceutical industry has, in the past decade, learned how to comply with change management and change control. Opportunity for improvement though still exists as Warning Letters as described above are still issued on this implied GMP requirement. No specific CMS guidance is mandated for pharmaceutical or clinical supplies companies, which leaves these companies to experiment with various approaches and systems; recent studies reveal that change is still tackled on a plant-specific and even projectbyproject basis, a relatively resourceintensive and impractical approach.1 In addition, change management processes are often still controlled manually, i.e., paperbased, or by a combination of both paperbased and digital CMS (i.e., hybrid) and with a decentralised solution compared with an enterprise-wide, centralised solution. This makes control, visibility and quality control unit action on change control and deviations rigid, if not impossible.
Paper-based quality management systems are fairly common especially in mid-sized FDA-regulated pharmaceutical companies as well as the clinical supplies industry. While such systems can successfully manage product and process quality, they can significantly increase the risk of GxP and especially GMP non-compliance. They also impede a pharmaceutical manufacturer's ability to implement continuous improvement initiatives in process and products. Finally, paper-based systems can potentially become a bottleneck to fast growth and capitalising on investments.
Overall, the pharmaceutical and clinical supplies industries still have difficulty in planning and executing GxP, and especially GMP-based change management practices according to their quality manual or equivalent documentation approach. In our opinion, depending on type and size, the number of changes in a pharmaceutical facility can range between 30 and 175 a month; these numbers stress the need for efficient management if randomness is to be removed. Randomness and lack of control exists, which causes non-compliance; approximately 40% of regulatory issues, including warning letters, regulatory inspection observations or compliance observations (CAPA etc.) are attributed to changes.2
To properly evaluate, approve and implement changes, pharmaceutical and clinical supplies companies (after the production of the phase III clinical batch) should have an effective CMS that ensures continual improvements are undertaken in a timely, prioritised and effective manner while providing a high degree of assurance that no unintended consequences of the change exists (In the absence of FDA guidance on CMS, however, valuable inspiration can be found at a rather untraditional federal agency — The US Occupational Health and Safety Administration using 29 CFR 1910.119, Process Safety Management, a section that offers a useful model for pharmaceutical companies for managing change).
Table 1: Application of CMS throughout product lifecycle.
The CMS should include the following as appropriate for the stage of the product lifecycle (Table 1):
Significant organisational and cultural barriers should also be addressed. Teams should meet often instead of once a quarter or less, and these teams should use an appropriate set of metrics to track changes and drive process improvements.
To effectively deal with these basic CMS requirements, life science companies need to be more agile and, as such, have a well-organised, enterprise-wide response to change. Ideally, effective management and structuring of product- and processengineering change can lead to reduced cycle times, quick responses to changing market conditions and increased rates of product innovation. Companies applying an integrated approach to managing change can innovate more quickly, promote compliance with global and regional regulations and better support a profitable, enterprisewide response to innovative and effective production processes as well as customer demand.
A new paradigm for managing change in an ideal environment is electronic-based CMS; a solution that smoothly complies with the above mentioned requirements and provides a means of bypassing potential barriers and obstacles.
An electronic based CMS should:
There has been a significant improvement in change management in the pharmaceutical industry over the last decade. The industry is on the right track and performs relatively better than it did up to 5 years ago when ineffective change management was responsible for the issuance of a significant portion of FDA Warning Letters.
(PATRICK KALYANAPU/GETTY IMAGES)
From a strategic point of view, however, there is still an opportunity for improvement. Fortunately, the changing dynamics of the pharmaceutical industry now reveal a trend towards a new strategic paradigm in favour of electronic, automated and, where applicable, enterprisewide change management systems. The trend is also forecasted for the clinical supplies industry. This approach provides top management, quality executives and engineers with instant access to the status of any change request, i.e., realtime transparency on trivial but formerly timeconsuming details (e.g., who has reviewed the revised document, who is sitting on the approval request and needs to be prompted, and who else needs to review it). The cycle time of review is therefore significantly reduced once the process is automated. Using this new approach also enables outofspecification problems, nonconformance issues and corrective actions to be tracked automatically, allowing users to have full access to details relating to nonconformance issues that have not been resolved or corrective actions that are waiting to be implemented.
Henrik Johanning is CEO and specialist, Genau & Co, Denmark. He is also a member of Pharmaceutical Technology Europe's Editorial Advisory Board.
John Y. Lee is Executive Director (Former FDA Investigator) at Pharmaceutical Compliance Associates, US.
Christian Hemmingsen is Chief Technology Officer, QAtor A/S, Denmark.
1. European Compliance Academy www.gmp-compliance.org
2. FDA www.fda.gov
3. ICH, Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Quality Risk Management Q9 www.ich.org